The Italian Thyroid Cancer Observatory (ITCO) repository was established to collect data on thyroid cancer management in a prospective and consecutive series of newly-diagnosed patients, enrolled in centers uniformly distributed across the nation.
Little information is available on current practices in the treatment of thyroid cancer: a web-based thyroid cancer database was created to collect real-life data. The participants' network include tertiary referral centers operating at the national level, as well as smaller hospital-based units with local or regional recruitment areas.
Study Type
OBSERVATIONAL
Enrollment
15,000
e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance
Disease persistence or recurrence
Composite event of disease persistence or recurrence during clinical follow-up, detected by any of the available imaging tools (neck sonography, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])
Time frame: Up to 10 years from the primary treatment
Disease persistence after 12-18 months from the primary treatment
Rate of disease persistence after 12-18 months from the primary treatment, detected by any of the available imaging tools (neck sonography, radioiodine whole body scan, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])
Time frame: 12-18 months from the primary treatment
Disease recurrence after 3, 5 and 10 years from the primary treatment
Rate of disease recurrence after 3, 5 and 10 years from the primary treatment, detected by any of the available imaging tools (neck sonography, radioiodine whole body scan, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])
Time frame: 3, 5 and 10 years from the primary treatment
Response to primary therapy
Response to primary treatment, evaluated according to the American Thyroid Association guidelines response to treatment: excellent response, biochemical incomplete response, indeterminate response, or structural incomplete response (combination of serum tumor markers and imaging tools, such as neck sonography, radioiodine whole body scan, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])
Time frame: 1, 3, 5 and 10 years after therapy
Response to secondary treatments
Response to secondary treatments, evaluated according to the American Thyroid Association guidelines response to treatment: excellent response, biochemical incomplete response, indeterminate response, or structural incomplete response (combination of serum tumor markers and imaging tools, such as neck sonography, radioiodine whole body scan, computed tomography \[CT\], magnetic resonance imaging \[MRI\], or positron emission tomography \[PET\])
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
A.S.S.T. Grande Ospedale Metropolitano Niguarda
Milan, Milano, Italy
RECRUITINGFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Milano, Italy
RECRUITINGIRCCS Ospedale San Raffaele
Milan, Milano, Italy
RECRUITINGOspedale Regina Apostolorum
Albano Laziale, RM, Italy
RECRUITINGOspedali Riuniti di Ancona
Ancona, Italy
RECRUITINGUniversità degli Studi di Bari
Bari, Italy
RECRUITINGOspedale degli Infermi di Biella
Biella, Italy
RECRUITINGAzienda Unità Sanitaria di Bologna - Ospedale Maggiore
Bologna, Italy
RECRUITINGUniversity of Bologna, S. Orsola Malpighi Hospital
Bologna, Italy
RECRUITINGUniversità degli Studi di Brescia, Spedali Civili
Brescia, Italy
RECRUITING...and 25 more locations
Time frame: 1, 3, 5 and 10 years after therapy